Diabetes, bone and glucose-lowering agents: basic biology

Beata Lecka-Czernik, Beata Lecka-Czernik

Abstract

Skeletal fragility often accompanies diabetes and does not appear to correlate with low bone mass or trauma severity in individuals with diabetes. Instead (and in contrast to those with osteoporotic bone disease), bone remodelling and bone turnover are compromised in both type 1 and type 2 diabetes, contributing to defective bone material quality. This review is one of a pair discussing the relationship between diabetes, bone and glucose-lowering agents; an accompanying review is provided in this issue of Diabetologia by Ann Schwartz (DOI: 10.1007/s00125-017-4283-6 ). This review presents basic science evidence that, alongside other organs, bone is affected in diabetes via impairments in glucose metabolism, toxic effects of glucose oxidative derivatives (advance glycation end-products [AGEs]), and via impairments in bone microvascular function and muscle endocrine function. The cellular and molecular basis for the effects of diabetes on bone are discussed, as is the impact of diabetes on the stem cell niche and fracture healing. Furthermore, the safety of clinically approved glucose-lowering therapies and the possibility of developing a single therapy that would be beneficial for both insulin sensitisation and diabetes bone syndrome are outlined.

Keywords: AGEs; Bone quality; Bone remodelling; Bone vasculature; Glucose; Glucose-lowering therapies; Muscle; Osteoblast; Osteoclast; Review; Stem cells.

Conflict of interest statement

Funding

This work was supported by grants from NIH DK105825 and the American Diabetes Association ADA 7-13-BS-089.

Duality of interest

The author declares that there is no duality of interest associated with this manuscript.

Contribution statement

BLC was the sole contributor to this paper.

Figures

Fig. 1
Fig. 1
Graphical summation of the effects of diabetes on bone. Impairments in glucose and insulin metabolism have indirect and direct effects on bone quality in individuals with diabetes. Impaired glucose/insulin metabolism may indirectly affect bone by altering skeletal muscle signalling. Furthermore, in metabolic disease, the accumulation of AGEs may trigger pathways that promote collagen cross-linking (altering bone biomechanics) and impact on bone remodelling. Furthermore, the bone vasculature is disturbed with dysregulation in glucose and insulin metabolism, so that the delivery of nutrients and signalling factors (e.g. that regulate vasodilation) to the bone is impaired. The changes in bone vasculature in diabetes results in decreased remodelling activity in the bone. Impairments in glucose and insulin metabolism also directly impact on osteoblast and osteoclast activity, resulting in decreased bone formation and bone resorption. Ultimately, the indirect and direct effects of impaired glucose/insulin metabolism on bone lead to decreased bone remodelling/turnover, decreased bone quality and increased risk of fractures

References

    1. Schwartz AV (2017) Diabetes, bone and glucose-lowering agents: clinical outcomes. Diabetologia. doi: 10.1007/s00125-017-4283-6
    1. Starup-Linde J, Frost M, Vestergaard P, Abrahamsen B. Epidemiology of fractures in diabetes. Calcif Tissue Int. 2017;100:109–121. doi: 10.1007/s00223-016-0175-x.
    1. Farr JN, Drake MT, Amin S, Melton LJ, 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014;29:787–795. doi: 10.1002/jbmr.2106.
    1. Lecka-Czernik B, Rosen CJ. Energy excess, glucose utilization, and skeletal remodeling: new insights. J Bone Miner Res. 2015;30:1356–1361. doi: 10.1002/jbmr.2574.
    1. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44:775–782. doi: 10.2337/diab.44.7.775.
    1. Rubin MR. Bone cells and bone turnover in diabetes mellitus. Curr Osteoporos Rep. 2015;13:186–191. doi: 10.1007/s11914-015-0265-0.
    1. Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28:313–324. doi: 10.1002/jbmr.1763.
    1. Nilsson AG, Sundh D, Johansson L, et al. Type 2 diabetes mellitus is associated with better bone microarchitecture but lower bone material strength and poorer physical function in elderly women: a population-based study. J Bone Miner Res. 2016
    1. Wei J, Shimazu J, Makinistoglu MP, et al. Glucose uptake and Runx2 synergize to orchestrate osteoblast differentiation and bone formation. Cell. 2015;161:1576–1591. doi: 10.1016/j.cell.2015.05.029.
    1. Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res. 2011;26:677–680. doi: 10.1002/jbmr.321.
    1. Ferron M, Wei J, Yoshizawa T, et al. Insulin signalling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142:296–308. doi: 10.1016/j.cell.2010.06.003.
    1. Kondegowda NG, Fenutria R, Pollack IR, et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-kappaB ligand pathway. Cell Metab. 2015;22:77–85. doi: 10.1016/j.cmet.2015.05.021.
    1. Fulzele K, Riddle RC, Digirolamo DJ, et al. Insulin receptor signalling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142:309–319. doi: 10.1016/j.cell.2010.06.002.
    1. Wei J, Ferron M, Clarke CJ, et al. Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest. 2014;124:1–13. doi: 10.1172/JCI72323.
    1. Doucette CR, Horowitz MC, Berry R, et al. A high fat diet increases bone marrow adipose tissue (MAT) but does not alter trabecular or cortical bone mass in C57BL/6J mice. J Cell Physiol. 2015;230:2032–2037. doi: 10.1002/jcp.24954.
    1. Lecka-Czernik B, Stechschulte LA, Czernik PJ, Dowling AR. High bone mass in adult mice with diet-induced obesity results from a combination of initial increase in bone mass followed by attenuation in bone formation; implications for high bone mass and decreased bone quality in obesity. Mol Cell Endocrinol. 2015;410:35–41. doi: 10.1016/j.mce.2015.01.001.
    1. Stechschulte LA, Czernik PJ, Rotter ZC, et al. PPARG post-translational modifications regulate bone formation and bone resorption. EBioMedicine. 2016;10:174–184. doi: 10.1016/j.ebiom.2016.06.040.
    1. Lecka-Czernik B. PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep. 2010;8:84–90. doi: 10.1007/s11914-010-0016-1.
    1. Ge C, Cawthorn WP, Li Y, Zhao G, MacDougald OA, Franceschi RT. Reciprocal control of osteogenic and adipogenic differentiation by ERK/MAP kinase phosphorylation of Runx2 and PPARgamma transcription factors. J Cell Physiol. 2016;231:587–596. doi: 10.1002/jcp.25102.
    1. Stechschulte LA, Ge C, Hinds TD, Jr, Sanchez ER, Franceschi RT, Lecka-Czernik B. Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPARgamma (peroxisome proliferator-activated receptor gamma) and RUNX2 (runt-related transcription factor 2) J Biol Chem. 2016;291:24475–24486. doi: 10.1074/jbc.M116.752493.
    1. Wei W, Wang X, Yang M, Smith LC, Dechow PC, Wan Y. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 2010;11:503–516. doi: 10.1016/j.cmet.2010.04.015.
    1. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148:2669–2680. doi: 10.1210/en.2006-1587.
    1. Abdallah BM, Ditzel N, Laborda J, Karsenty G, Kassem M. DLK1 regulates whole-body glucose metabolism: a negative feedback regulation of the osteocalcin-insulin loop. Diabetes. 2015;64:3069–3080. doi: 10.2337/db14-1642.
    1. Tevlin R, Seo EY, Marecic O, et al. Pharmacological rescue of diabetic skeletal stem cell niches. Sci Transl Med. 2017;9:eaag2809. doi: 10.1126/scitranslmed.aag2809.
    1. Creecy A, Uppuganti S, Merkel AR, et al. Changes in the fracture resistance of bone with the progression of type 2 diabetes in the ZDSD rat. Calcif Tissue Int. 2016;99:289–301. doi: 10.1007/s00223-016-0149-z.
    1. Aikawa E, Fujita R, Asai M, Kaneda Y, Tamai K. Receptor for advanced glycation end products-mediated signalling impairs the maintenance of bone marrow mesenchymal stromal cells in diabetic model mice. Stem Cells Dev. 2016;25:1721–1732. doi: 10.1089/scd.2016.0067.
    1. Ding KH, Wang ZZ, Hamrick MW, et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun. 2006;340:1091–1097. doi: 10.1016/j.bbrc.2005.12.107.
    1. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:2380–2386. doi: 10.1210/jc.2008-2498.
    1. Lafage-Proust MH, Roche B, Langer M, et al. Assessment of bone vascularization and its role in bone remodeling. Bonekey Rep. 2015;4:662. doi: 10.1038/bonekey.2015.29.
    1. Weber DR, Haynes K, Leonard MB, Willi SM, Denburg MR. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using the health improvement network (THIN) Diabetes Care. 2015;38:1913–1920. doi: 10.2337/dc15-0783.
    1. Shanbhogue VV, Hansen S, Frost M, et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol. 2016;174:115–124. doi: 10.1530/EJE-15-0860.
    1. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res. 2009;46:572–580. doi: 10.1159/000226225.
    1. Gohin S, Carriero A, Chenu C, Pitsillides AA, Arnett TR, Marenzana M. The anabolic action of intermittent parathyroid hormone on cortical bone depends partly on its ability to induce nitric oxide-mediated vasorelaxation in BALB/c mice. Cell Biochem Funct. 2016;34:52–62. doi: 10.1002/cbf.3164.
    1. Eckardt K, Gorgens SW, Raschke S, Eckel J. Myokines in insulin resistance and type 2 diabetes. Diabetologia. 2014;57:1087–1099. doi: 10.1007/s00125-014-3224-x.
    1. Yang X, Ricciardi BF, Hernandez-Soria A, Shi Y, Pleshko Camacho N, Bostrom MP. Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. Bone. 2007;41:928–936. doi: 10.1016/j.bone.2007.07.022.
    1. Mera P, Laue K, Ferron M, et al. Osteocalcin signalling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 2016;23:1078–1092. doi: 10.1016/j.cmet.2016.05.004.
    1. Colaianni G, Cuscito C, Mongelli T, et al. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci U S A. 2015;112:12157–12162. doi: 10.1073/pnas.1516622112.
    1. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 2014;37:1367–1374. doi: 10.2337/dc13-2289.
    1. Jang WG, Kim EJ, Bae IH, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone. 2011;48:885–893. doi: 10.1016/j.bone.2010.12.003.
    1. Chen SC, Brooks R, Houskeeper J, et al. Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms. Mol Cell Endocrinol. 2017;440:57–68. doi: 10.1016/j.mce.2016.11.011.
    1. Zhou Z, Tang Y, Jin X, et al. Metformin inhibits advanced glycation end products-induced inflammatory response in murine macrophages partly through AMPK activation and RAGE/NFkappaB pathway suppression. J Diabetes Res. 2016;2016:4847812.
    1. Yu JW, Deng YP, Han X, Ren GF, Cai J, Jiang GJ. Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic mice. Cardiovasc Diabetol. 2016;15:88. doi: 10.1186/s12933-016-0408-3.
    1. Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011;112:2902–2909. doi: 10.1002/jcb.23206.
    1. Ma P, Gu B, Xiong W, et al. Glimepiride promotes osteogenic differentiation in rat osteoblasts via the PI3K/Akt/eNOS pathway in a high glucose microenvironment. PLoS One. 2014;9:e112243. doi: 10.1371/journal.pone.0112243.
    1. Fronczek-Sokol J, Pytlik M. Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats. Pharmacol Rep. 2014;66:412–417. doi: 10.1016/j.pharep.2013.12.013.
    1. Pereira M, Jeyabalan J, Jorgensen CS, et al. Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone. 2015;81:459–467. doi: 10.1016/j.bone.2015.08.006.
    1. Thrailkill KM, Nyman JS, Bunn RC, et al. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone. 2016;82:101–107. doi: 10.1016/j.bone.2015.07.025.
    1. Lecka-Czernik B (2010) Bone loss in diabetes: use of anti-diabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporosis Rep 8:178–184
    1. Mieczkowska A, Basle MF, Chappard D, Mabilleau G. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem. 2012;287:23517–23526. doi: 10.1074/jbc.M111.324814.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir